BASF has signed a research and development agreement with Poietis to apply its 3D laser-assisted bioprinting technology to improve BASF’s skin equivalent model Mimeskin™.
The technology reproduces skin cells in 3D structures within Mimeskin™, a closest equivalent to the physiological tissue of human skin. More advanced models containing additional cell types will also be developed using the technology.
Dr. Sebastien Cadau, responsible for tissue engineering development at BASF, says “Compared to other bioprinting methods the laser-assisted technology provides higher resolution when it comes to the patterning of cells. The partnership with Poietis allows BASF to secure its strategic advantage in better understanding the skin mechanisms which support the development and testing of advanced cosmetic bioactives for skin care applications.”
The partnership also emphasizes bioprinted tissue models as an alternative to animal testing in cosmetics and dermopharmacy. The terms and conditions of the agreement were not disclosed.